These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35141008)

  • 21. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
    Lehmann BD; Abramson VG; Dees EC; Shah PD; Ballinger TJ; Isaacs C; Santa-Maria CA; An H; Gonzalez-Ericsson PI; Sanders ME; Newsom KC; Abramson RG; Sheng Q; Hsu CY; Shyr Y; Wolff AC; Pietenpol JA
    JAMA Oncol; 2024 Feb; 10(2):193-201. PubMed ID: 38095878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.
    Wu B; Ma F
    Ther Adv Med Oncol; 2020; 12():1758835920916000. PubMed ID: 32426048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma.
    Bergsma EJ; Elgawly M; Mancuso D; Orr R; Vuskovich T; Seligson ND
    Ann Pharmacother; 2024 Apr; 58(4):407-415. PubMed ID: 37466080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
    Chisaki Y; Kuwada Y; Matsumura C; Yano Y
    Clin Drug Investig; 2021 Apr; 41(4):381-389. PubMed ID: 33674955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
    Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
    J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab and atezolizumab in triple-negative breast cancer.
    Kwapisz D
    Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atezolizumab for the treatment of breast cancer.
    Reddy SM; Carroll E; Nanda R
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):151-158. PubMed ID: 32067545
    [No Abstract]   [Full Text] [Related]  

  • 28. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
    Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
    Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
    Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
    Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
    Liu X; Lang Y; Liao Y; Zhu Y
    Front Public Health; 2021; 9():756899. PubMed ID: 34778188
    [No Abstract]   [Full Text] [Related]  

  • 31. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
    Wang H; Ma H; Sové RJ; Emens LA; Popel AS
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.
    Sharmni Vishnu K; Win TT; Aye SN; Basavaraj AK
    BMC Cancer; 2022 Nov; 22(1):1139. PubMed ID: 36335316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
    Adams S; Diéras V; Barrios CH; Winer EP; Schneeweiss A; Iwata H; Loi S; Patel S; Henschel V; Chui SY; Rugo HS; Emens LA; Schmid P
    Ann Oncol; 2020 May; 31(5):582-589. PubMed ID: 32178964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.
    Inman BA; Longo TA; Ramalingam S; Harrison MR
    Clin Cancer Res; 2017 Apr; 23(8):1886-1890. PubMed ID: 27903674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
    Gianni L; Huang CS; Egle D; Bermejo B; Zamagni C; Thill M; Anton A; Zambelli S; Bianchini G; Russo S; Ciruelos EM; Greil R; Semiglazov V; Colleoni M; Kelly C; Mariani G; Del Mastro L; Maffeis I; Valagussa P; Viale G
    Ann Oncol; 2022 May; 33(5):534-543. PubMed ID: 35182721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding PD-L1 Testing in Breast Cancer: A Practical Approach.
    Erber R; Hartmann A
    Breast Care (Basel); 2020 Oct; 15(5):481-490. PubMed ID: 33223991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.
    Uchimiak K; Badowska-Kozakiewicz AM; Sobiborowicz-Sadowska A; Deptała A
    Clin Med Insights Oncol; 2022; 16():11795549221099869. PubMed ID: 35721387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.